---
schema_version: "secwatch.filing_event.v1"
accession: "0001787306-23-000081"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2023-08-18T23:59:59+00:00"
generated_at: "2026-06-11T07:00:05.767603+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcutis CFO Scott Burrows resigns; former CFO John Smither named interim CFO

## Summary
- Scott Burrows resigns as CFO effective Aug 31, 2023 to pursue external opportunity; no disagreement with company.
- John Smither, Arcutis' first CFO (2019-2021), appointed interim CFO effective Aug 31, 2023.
- Smither has over 25 years pharma finance experience, including CFO roles at Kythera, Unity, Sienna, and interim CFO at Kite.
- Smither will serve as principal financial and accounting officer; compensation terms to be disclosed later.
- Company has commenced search for permanent CFO.

## SEC filing metadata
- accession: 0001787306-23-000081
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2023-08-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000081/0001787306-23-000081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000081/arqt-20230815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787306-23-000081
- JSON: https://secwatch.observer/filing/0001787306-23-000081.json
- Plain text: https://secwatch.observer/filing/0001787306-23-000081.txt

## Key facts
- Executive change
  Scott Burrows resigned as chief financial officer at Arcutis Biotherapeutics, Inc..
  - Action: resigned
  - Role: chief financial officer
  source text: On August 15, 2023, Scott Burrows notified Arcutis Biotherapeutics, Inc. (the “Company”) of his decision to resign as chief financial officer of the Company, effective as of August 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000081/0001787306-23-000081-index.htm
- Executive change
  John Smither was appointed as interim chief financial officer at Arcutis Biotherapeutics, Inc..
  - Action: appointed
  - Role: interim chief financial officer
  source text: The Company has commenced a search for a permanent chief financial officer and has appointed John Smither, who previously served as the Company’s chief financial officer from May 2019 until his retirement in March 2021, as interim chief financial officer, effective upon Mr. Burrows’ departure from the Company on August 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787306/000178730623000081/0001787306-23-000081-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.